Last reviewed · How we verify
etonogestrel-releasing implant contraceptive
etonogestrel-releasing implant contraceptive is a Progestin contraceptive Small molecule drug developed by University of Sao Paulo. It is currently FDA-approved for Contraception in women of reproductive age. Also known as: implanon.
Etonogestrel is a progestin that prevents pregnancy by suppressing ovulation and thickening cervical mucus.
Etonogestrel is a progestin that prevents pregnancy by suppressing ovulation and thickening cervical mucus. Used for Contraception in women of reproductive age.
At a glance
| Generic name | etonogestrel-releasing implant contraceptive |
|---|---|
| Also known as | implanon |
| Sponsor | University of Sao Paulo |
| Drug class | Progestin contraceptive |
| Target | Progesterone receptor |
| Modality | Small molecule |
| Therapeutic area | Contraception |
| Phase | FDA-approved |
Mechanism of action
Etonogestrel is a synthetic progestin released continuously from a subdermal implant over 3 years. It acts on the hypothalamic-pituitary-ovarian axis to inhibit the LH surge necessary for ovulation, while also increasing cervical mucus viscosity to impede sperm transport. This dual mechanism provides highly effective contraception with typical use failure rates below 1%.
Approved indications
- Contraception in women of reproductive age
Common side effects
- Irregular bleeding or amenorrhea
- Headache
- Acne
- Breast tenderness
- Weight gain
- Mood changes
- Insertion site pain or infection
Key clinical trials
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Body Composition and Sport Performance Among Young Female Soccer Players Using Subdermic Etonogestrel (EARLY_PHASE1)
- Treatment of Prolonged Uterine Bleeding of Etonogestrel (ENG)-Releasing Implant (PHASE4)
- Progesterone Containing Contraceptive Methods on Endogenous Progesterone Level
- A Multicenter Trial to Evaluate the Insertion Characteristics of the Radiopaque Etonogestrel Implant Using a Next Generation Applicator (34530)(P05702) (PHASE3)
- A Bioequivalence Study of IMPLANON and Radiopaque IMPLANON (34528)(P05720) (PHASE3)
- Contraception in Women With Sickle Cell Disease (PHASE4)
- Effect of Dolutegravir on Etonogestrel Levels in HIV-infected Women in Botswana
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- etonogestrel-releasing implant contraceptive CI brief — competitive landscape report
- etonogestrel-releasing implant contraceptive updates RSS · CI watch RSS
- University of Sao Paulo portfolio CI
Frequently asked questions about etonogestrel-releasing implant contraceptive
What is etonogestrel-releasing implant contraceptive?
How does etonogestrel-releasing implant contraceptive work?
What is etonogestrel-releasing implant contraceptive used for?
Who makes etonogestrel-releasing implant contraceptive?
Is etonogestrel-releasing implant contraceptive also known as anything else?
What drug class is etonogestrel-releasing implant contraceptive in?
What development phase is etonogestrel-releasing implant contraceptive in?
What are the side effects of etonogestrel-releasing implant contraceptive?
What does etonogestrel-releasing implant contraceptive target?
Related
- Drug class: All Progestin contraceptive drugs
- Target: All drugs targeting Progesterone receptor
- Manufacturer: University of Sao Paulo — full pipeline
- Therapeutic area: All drugs in Contraception
- Indication: Drugs for Contraception in women of reproductive age
- Also known as: implanon
- Compare: etonogestrel-releasing implant contraceptive vs similar drugs
- Pricing: etonogestrel-releasing implant contraceptive cost, discount & access